Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

All Participants: Inclusion Criteria: * Male and non-child bearing potential female participants, 18 to 75 years of age (inclusive) at Screening. * Participants must weigh at least 50.0 kg and must have a body mass index (BMI) within the range of 18.0 to 38.0 kg/m2, inclusive, at Screening. * Must be a non-smoker or agree to smoke no more than 5 cigarettes (or equivalent) per day from Screening until the End of Study. Participants must maintain the same smoking status throughout the study (i.e. smoker or non smoker). Exclusion Criteria: * Use of other investigational drugs within 5 half-lives prior to dosing of study treatment, or within 30 days, whichever is longer; or longer if required by local regulations. * Are taking medications prohibited to be taken with the study treatment * Known history of, or current clinically significant arrhythmias. Have clinically significant ECG abnormality or history of long-QT syndrome or whose QT interval corrected by Fridericia's formula (QTcF) is prolonged (\> 480 msec) at Screening. Participants having myocardial infarction ≥ 5 years ago are eligible to participate. * Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection. Healthy Participants: * Each participant must match in age (± 10 years), gender, weight (± 15%), and smoking status to participants in Group 2, 3, or 4. * Seated vital signs must be within the following ranges at Screening and Baseline: * Body temperature, 35.0 to 37.5°C, inclusive. * Systolic blood pressure, 89 to 149 mmHg, inclusive. * Diastolic blood pressure, 50 to 89 mmHg, inclusive. * Pulse rate, 40 to 90 bpm, inclusive. * Participants must be in good health as determined by medical history, physical examination, ECG, and clinical laboratory tests at Screening. Exclusion Criteria: * Liver disease or liver injury as indicated by abnormal liver function tests. * Chronic infection with HBV or HCV. * History or presence of impaired renal function. Hepatic Impairment Participants: Inclusion Criteria: * Seated vital signs must be within the following ranges at Screening and Baseline: * Body temperature, 35.0 to 37.5°C, inclusive. * Systolic blood pressure, 89 to 159 mmHg, inclusive. * Diastolic blood pressure, 50 to 99 mmHg, inclusive. * Pulse rate, 50 to 99 bpm, inclusive. * Hepatic impairment as defined by the Child-Pugh classification for severity of liver disease Exclusion Criteria: * Have severe complications of liver disease within the preceding 3 months of Screening. * Emergency room visit or hospitalization due to liver disease within the preceding 3 months of Screening. * Have received liver transplant at any time in the past. * Have encephalopathy Grade 3 or worse within 28 days prior to dosing of study treatment. * Have acute hepatitis B (HBV) or hepatitis C (HCV) infection. * Clinically significant abnormal findings in physical examination or clinical laboratory evaluations not consistent with known liver disease. Other protocol-defined inclusion/exclusion criteria may apply